What You Should Know
- GE HealthCare officially launched Invenia™ ABUS (Automated Breast Ultrasound) Prime and ABUS StreamVue™, extending its diagnostic ultrasound portfolio targeting dense breast tissue.
- ABUS StreamVue received U.S. FDA 510(k) clearance and CE Marking as a zero-footprint, browser-based reading platform developed in collaboration with Candelis, Inc. to enable remote multi-site exam review.
- Dense breasts affect approximately 40% of women across the U.S. and Europe, elevating breast cancer risk by 4x to 6x and causing mammograms to miss roughly one-third of tumors.
- Invenia ABUS Prime features Verisound™ AI-powered tools (Scan Quality Assessment, Auto Nipple Detection), a Fast Scan tool that speeds up scans by up to 40%, and QVCAD™ AI reading support that reduces read times by 33%.
- Los Angeles-based imaging provider BeSound represents one of the first U.S. clinical installations of Invenia ABUS Prime, with plans to launch a mobile screening unit to expand community access.
GE HealthCare Expands Breast Imaging Portfolio with Invenia ABUS Prime and StreamVue
Approximately 40% of women in the U.S. and Europe have dense breasts, a physiological factor that increases breast cancer risk four- to six-fold while rendering standard 2D mammography less effective. Because dense fibroglandular tissue and cancerous lesions both appear white on mammograms, mammography alone can miss up to one-third of malignancies in dense-breasted patients. To standardize 3D ultrasound acquisition and streamline multi-site interpretation across healthcare networks, GE HealthCare has launched Invenia™ ABUS Prime alongside ABUS StreamVue™.
GE HealthCare’s latest deployment brings together automated 3D hardware and a flexible, web-based viewer to streamline supplemental breast screening. Built on the Invenia ABUS Prime platform and powered by the cSound™ Imageformer and Verisound™ software, the system relies on automated quality checks and nipple detection to deliver consistent 3D scans across disparate imaging sites. Patient experience and throughput get a boost from a redesigned Reverse Curve™ transducer, tailored compression controls, and a Fast Scan setting that trims acquisition time by up to 40%. For radiologists, embedded QVCAD™ triage assists with reader decision-making—reducing interpretation time by a third while keeping lesion detection sensitivity at 93%.
To handle remote reads, the setup integrates Candelis, Inc.’s FDA-cleared ABUS StreamVue viewer, allowing clinicians to review cases securely in a browser without installing local software. The full architecture is currently operational at BeSound in Los Angeles for outpatient screening, with plans to expand the model into mobile units.
“Invenia ABUS Prime builds on our commitment to advancing supplemental breast screening for women with dense breasts,” stated Karley Yoder, CEO of Ultrasound Solutions at GE HealthCare. “As breast imaging networks look to scale across sites, Invenia ABUS Prime can help deliver streamlined workflows, reproducible imaging, with features designed to support both patient comfort and clinician efficiency.”
